Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents.
Wang, Z., Li, D., Chen, Y., Sun, Y., Jin, C., Hu, C., Feng, Y., Su, J., Ren, L., Hao, Y., Wang, S., Zhu, M., Liu, Y., Qi, J., Zhu, B., Shao, Y.(2023) Front Immunol 14: 1160283-1160283
- PubMed: 37234155 
- DOI: https://doi.org/10.3389/fimmu.2023.1160283
- Primary Citation of Related Structures:  
8HN6, 8HN7 - PubMed Abstract: 
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been posing a severe threat to global public health. Although broadly neutralizing antibodies have been used to prevent or treat corona virus disease 2019 (COVID-19), new emerging variants have been proven resistant to these antibodies.
Organizational Affiliation: 
State Key Laboratory of Infectious Disease Prevention and Control, Division of Research of Virology and Immunology, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.